Multicentre, placebo-controlled trial of lorcaserin for weight management in Chinese population
Journal
Obesity Research and Clinical Practice
Journal Volume
12
Journal Issue
5
Pages
465-471
Date Issued
2018
Author(s)
Abstract
Objective: This study aimed to evaluate the effects of lorcaserin on body weight, cardiovascular risk factors, and safety in obese patients in Taiwan. Methods: In this double-blind, randomised controlled trial, 171 obese adults were assigned to receive lorcaserin at a dose of 10 mg, or placebo, twice a day for 24 weeks. Diet and exercise counselling were given to all patients through the treatment period. Primary outcomes were proportion of patients achieving at least 5% and 10% reduction in body weight and mean change in body weight. Safety and tolerability endpoints such as Beck Depression Inventory-II, blood biochemistry, vital signs, and electrocardiogram were monitored. Results: More patients receiving lorcaserin lost at least 5% body weight than receiving placebo (52.4% and 28.1%, P = 0.001) with an average weight reduction of 5.8 kg (95% CI: ?6.91, ?4.70) in lorcaserin group and those of 3.6 kg (95% CI: ?4.95, ?2.33) in placebo group (P < 0.05). The most common adverse effect with greater incidence in the lorcaserin group was self-limited dizziness. Serious adverse effect were rare and was reported by slightly more patients taking placebo than lorcaserin. Conclusions: In this multicentre, double-blinded placebo-controlled trial, lorcaserin was effective and well-tolerable in Asia group. ? 2018 Asia Oceania Association for the Study of Obesity
SDGs
Other Subjects
glycosylated hemoglobin; high density lipoprotein cholesterol; lorcaserin; low density lipoprotein cholesterol; placebo; triacylglycerol; antiobesity agent; benzazepine derivative; lorcaserin; adult; aged; Article; backache; Beck Depression Inventory; blood biochemistry; body mass; body weight; body weight loss; cardiovascular risk; Chinese; constipation; controlled study; coughing; diarrhea; diastolic blood pressure; dizziness; double blind procedure; drug safety; drug tolerability; electrocardiogram; exercise; fatigue; female; headache; hepatobiliary disease; human; major clinical study; male; metabolic disorder; nausea; obese patient; outcome assessment; patient counseling; priority journal; quality of life assessment; randomized controlled trial; rhinopharyngitis; rhinorrhea; systolic blood pressure; upper respiratory tract infection; vital sign; vomiting; waist circumference; Asian continental ancestry group; cardiovascular disease; clinical trial; drug effect; heart rate; middle aged; multicenter study; obesity; treatment outcome; young adult; Adult; Anti-Obesity Agents; Asian Continental Ancestry Group; Benzazepines; Body Mass Index; Cardiovascular Diseases; Double-Blind Method; Female; Heart Rate; Humans; Male; Middle Aged; Obesity; Treatment Outcome; Weight Loss; Young Adult
Publisher
Elsevier Ltd
Type
journal article